On October 7, 2021 Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET to announce its next clinical product candidates (Press release, Gossamer Bio, OCT 7, 2021, View Source [SID1234590955]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Gossamer management will present and discuss its forthcoming additions to its clinical product candidate pipeline. As part of the event, Gossamer Bio management will be available for questions.
Conference Call and Webcast
Gossamer will host a conference call and live audio webcast at 2:30 pm ET on Monday, October 11. The live audio webcast may be accessed through the "Events / Presentations" page in the "Investors" section of the Company’s website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:
Conference ID: 4165598
Domestic Dial-in Number: (833) 646-0603
International Dial-in Number: (929) 517-9782
Live Webcast: View Source
A replay of the audio webcast will be available for 30 days on the "Investors" section of the Company’s website, www.gossamerbio.com.